Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Applied Health Economics and Health Policy
Erschienen in: Applied Health Economics and Health Policy 5/2015

01.10.2015 | Systematic Review

A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis

verfasst von: Barbara de Graaff, Amanda Neil, Kristy Sanderson, Lei Si, Kwang Chien Yee, Andrew J. Palmer

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Hereditary haemochromatosis (HH) is a common genetic condition amongst people of northern European heritage. HH is associated with increased iron absorption leading to parenchymal organ damage and multiple arthropathies. Early diagnosis and treatment prevents complications. Population screening may increase early diagnosis, but no programmes have been introduced internationally: a paucity of health economic data is often cited as a barrier.

Objective

To conduct a systematic review of all health economic studies in HH.

Methods

Studies were identified through electronic searching of economic/biomedical databases. Any study on HH with original economic component was included. Study quality was formally assessed. Health economic data were extracted and analysed through narrative synthesis.

Results

Thirty-eight studies met the inclusion criteria. The majority of papers reported on costs or cost effectiveness of screening programmes. Whilst most concluded screening was cost effective compared with no screening, methodological flaws limit the quality of these findings. Assumptions regarding clinical penetrance, effectiveness of screening, health-state utility values (HSUVs), exclusion of early symptomatology (such as fatigue, lethargy and multiple arthropathies) and quantification of costs associated with HH were identified as key limitations. Treatment studies concluded therapeutic venepuncture was the most cost-effective intervention.

Conclusions

There is a paucity of high-quality health economic studies relating to HH. The development of a comprehensive HH cost-effectiveness model utilising HSUVs is required to determine whether screening is worthwhile.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Allen K. Hereditary haemochromatosis—diagnosis and management. Aust Fam Physician. 2010;39(12):938–41.PubMed
3.
4.
Feder JN. The hereditary hemochromatosis gene (HFE): a MHC class I-like gene that functions in the regulation of iron homeostasis. Immunol Res. 1999;20(2):175–85.CrossRefPubMed
5.
Altes A, et al. Prevalence of the C282Y, H63D, and S65C mutations of the HFE gene in 1,146 newborns from a region of Northern Spain. Genet Test. 2004;8(4):407–10.CrossRefPubMed
6.
Pedersen P, Melsen GV, Milman N. Frequencies of the haemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol. 2008;87(9):735–40.CrossRefPubMed
7.
Gagne G, et al. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet. 2007;71(1):46–58.CrossRefPubMed
8.
Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 1999;94(6):1593–600.CrossRefPubMed
9.
Bacon BR, et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999;130(12):953–62.CrossRefPubMed
10.
Olynyk JK, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341(10):718–24.CrossRefPubMed
11.
Allen KJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358(3):221–30.CrossRefPubMed
12.
Mclaren CE, et al. Prevalence of heterozygotes for hemochromatosis in the white-population of the United-States. Blood. 1995;86(5):2021–7.PubMed
13.
Adams PC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–78.CrossRefPubMed
14.
Merryweather-Clarke A, et al. Geography of HFE C282Y and H63D mutations. Genet Test. 2000;4(3):183–98.CrossRefPubMed
15.
Biotechnology Australia, Genetics in Family Medicine: The Australian Handbook for General Practitioners: hereditary haemochromatosis, A.G.A.B. Australia, Editor. National Health and Medical Research Council: Canberra; 2007.
16.
Barton J, Edwards CQ. Hemochromatosis: genetics, patholphysiology, diagnosis and treatment. Cambridge: Cambridge University Press; 2000.CrossRef
17.
Byrnes V, et al. The underdiagnosis of hereditary haemochromatosis: lack of presentation or penetration, expectations based on a study of relatives of symptomatic probands. Gastroenterology. 2000;118(4):A997.
18.
Powell LW, Dixon JL, Hewett DG. Role of early case detection by screening relatives of patients with HFE-associated hereditary haemochromatosis. Best Pract Res Clin Haematol. 2005;18(2):221–34.CrossRefPubMed
19.
McDonnell SM, et al. Screening for hemochromatosis in primary care settings. Ann Intern Med. 1998;129(11):962–70.CrossRefPubMed
20.
Adams PC, et al. The relationship between iron overload, clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology. 1997;25(1):162–6.CrossRefPubMed
21.
Ajioka RS, Kushner JP. Clinical consequences of iron overload in hemochromatosis homozygotes. Blood. 2003;101(9):3351–3 (discussion 3354–8).
22.
Allen KJ, Warner B, Delatycki MB. Clinical haemochromatosis in HFE mutation carriers. Lancet. 2002;360(9330):412–3 (author reply 413–4).
23.
Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol. 1998;35(1):55–71.PubMed
24.
Niederau C, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110(4):1107–19.CrossRefPubMed
25.
European Association for the Study of the L. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010;53(1):3–22.CrossRef
26.
Muncunill J, et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apher. 2002;17(2):88–92.CrossRefPubMed
27.
Adams P, et al. Screening for iron overload: lessons from the hemochromatosis and iron overload screening (HEIRS) study. Can J Gastroenterol. 2009;23(11):769–72.PubMedCentralPubMed
28.
Gasser B, et al. Hereditary hemochromatosis: presenting manifestations and diagnostic delay. Hémochromatose héréditaire: circonstances de découverte et délais diagnostiques. 2013.
29.
Adams P, Brissot P, Powell L. EASL International Consensus Conference on Haemochromatosis—Part II. Expert document. J Hepatol. 2000;33(3):487–496.
30.
Mundy L, Merlin T. Population genetic screening for haemochromatosis: identifying asymptomatic “at risk” homozygous individuals. Horizon scanning prioritising summary—volume 1. Adelaide Health Technology Assessment (AHTA); 2003.
31.
Allen KJ. Population genetic screening for hereditary haemochromatosis: are we a step closer? Med J Aust. 2008;189(6):300–1.PubMed
32.
Asberg A, et al. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol. 2002;37(10):1212–9.CrossRefPubMed
33.
Barton JC, Acton RT. Population screening for hemochromatosis: has the time finally come? Curr Gastroenterol Rep. 2000;2(1):18–26.CrossRefPubMed
34.
Delatycki MB, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet. 2005;366(9482):314–6.CrossRefPubMed
35.
Gertig DM, Hopper JL, Allen KJ. Population genetic screening for hereditary haemochromatosis. Med J Aust. 2003;179(10):517–8.PubMed
36.
Niederau C, et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med. 1998;128(5):337–45.CrossRefPubMed
37.
Phatak PD, et al. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994;154(7):769–76.CrossRefPubMed
38.
Powell LW, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166(3):294–301.CrossRefPubMed
39.
Patch C, Roderick P, Rosenberg W. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis. J Hepatol. 2005;43(1):149–55.CrossRefPubMed
40.
Delatycki MB, et al. ironXS: high-school screening for hereditary haemochromatosis is acceptable and feasible. Eur J Hum Genet. 2012;20(5):505–9.PubMedCentralCrossRefPubMed
41.
Nisselle AE, et al. Implementation of HaemScreen, a workplace-based genetic screening program for hemochromatosis. Clin Genet. 2004;65(5):358–67.CrossRefPubMed
42.
Asberg A, et al. Screening for hemochromatosis: High prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol. 2001;36(10):1108–15.CrossRefPubMed
43.
Adams PC, et al. Screening for iron overload: Lessons from the HEmochromatosis and IRon Overload Screening (HEIRS) study. Can J Gastroenterol. 2009;23(11):769–72.PubMedCentralPubMed
44.
Bryant J, et al. Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation. Health Technol Assess. 2009;13(23):1–126.
45.
Allen KJ, et al. Asymptomatic individuals at genetic risk of haemochromatosis take appropriate steps to prevent disease related to iron overload. Liver Int. 2008;28(3):363–9.CrossRefPubMed
46.
Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol. 2003;98(9):2072–7.CrossRefPubMed
47.
Nadakkavukaran IM, Gan EK, Olynyk JK. Screening for hereditary haemochromatosis. Pathology. 2012;44(2):148–52.CrossRefPubMed
48.
Wilson JMG, Junger G. Priciples and practice of screening for disease. Geneva: Switzerland; 1968.
49.
Grosse SD, et al. Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics. 2010;13(2):106–15.CrossRefPubMed
50.
Campbell and Cochrane Economics Methods GrouCampbell and Cochrane Economics Methods Group, How to add Health Economics to Cochrane Protocols. Available from http://​www.​c-cemg.​org/​. Accessed 10 Oct 2011.
51.
Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, editors. Evidence-based decisions and economics: health care, social welfare, education and criminal justice. 2nd ed. Evidence-based medicine series. Chichester; Hoboken: Wiley-Blackwell/BMJ Books; 2010. p. 206.
52.
Drummond MF, et al. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
53.
Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–83.PubMedCentralCrossRefPubMed
54.
Dissemination C.f.R.a. Systematic reviews: CRD’s guidance for undertaking reviews in health care. 3rd ed. York: Centre for Reviews and Dissemination; 2009.
55.
Rombout-Sestrienkova E, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion. 2012;52(3):470–7.CrossRefPubMed
56.
Mariani R, et al. Erythrocytapheresis plus erythropoietin: An alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica. 2005;90(5):717–8.PubMed
57.
Stefashyna O, et al. Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre. Vox Sang. 2014;106(2):111–7.CrossRefPubMed
58.
Dye DE, et al. The impact of single gene and chromosomal disorders on hospital admissions in an adult population. J Community Genet. 2011;2(2):81–90.PubMedCentralCrossRefPubMed
59.
Gribble D, Chaffn DJ, Bryant BJ. Cost-effectiveness of fda variance for blood collection from individuals with hereditary hemochromatosis at a 398 bed hospital-based donor center. Transfusion. 2009;49:249A.
60.
Cooper K, et al. A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations. QJM. 2008;101(8):631–41.CrossRefPubMed
61.
Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterol Clin N Am. 1995;108:177–88.
62.
Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology (Baltimore, Md.). 1995;22(6):1720–27.
63.
Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994;154(7):769–76.CrossRefPubMed
64.
Schoffski O, Schmidtke J, Stuhrmann M. Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genet. 2000;3:2–11.CrossRef
65.
Bassett ML, et al. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol. 1997;27(3):517–24.CrossRefPubMed
66.
El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients—a cost-effectiveness analysis. Ann Intern Med. 2000;132(4):261–269.
67.
Buffone GJ, Beck JR. Cost-effectiveness analysis for evaluation of screening programs—hereditary hemochromatosis. Clin Chem. 1994;40(8):1631–6.PubMed
68.
Rogowski WH. The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. Med Decis Mak. 2009;29(2):224–38.CrossRef
69.
Stuhrmann M, Strassburg C, Schmidtke J. Genotype-based screening for hereditary haemochromatosis. I: technical performance, costs and clinical relevance of a German pilot study. Eur J Hum Genet. 2005;13(1):69–78.CrossRefPubMed
70.
Hickman PE, et al. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis. Gut. 2000;46(3):405–9.PubMedCentralCrossRefPubMed
71.
Stave GM, et al. Evaluation of a workplace hemochromatosis screening program. Am J Prev Med. 1999;16(4):303–6.CrossRefPubMed
72.
73.
Vardarli I, et al. In hospitalized patients with diabetes mellitus screening for hereditary hemochromatosis by using transferrin saturation is cost effective. Diabetologia. 2009;52(S1):S398–9.
74.
Smith BN, et al. Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is celtic origin a risk factor? Hepatology. 1997;25(6):1439–46.CrossRefPubMed
75.
Barton JC, et al. Hemochromatosis detection in a health screening program at an Alabama forest products mill. J Occup Environ Med. 2002;44(8):745–51.CrossRefPubMed
76.
Adams PC. Implications of genotyping of spouses to limit investigation of children in genetic hemochromatosis. Clin Genet. 1998;53(3):176–8.CrossRefPubMed
77.
Jacobs EM, et al. Impact of the introduction of a guideline on the targeted detection of hereditary haemochromatosis. Neth J Med. 2005;63(6):205–14.PubMed
78.
79.
Baer DM, et al. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med. 1995;98(5):464–8.CrossRefPubMed
80.
Adams PC, et al. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology. 2000;31(5):1160–4.CrossRefPubMed
81.
Balan V, et al. Screening for hemochromatosis—a cost-effectiveness study based on 12,258 patients. Gastroenterology. 1994;107(2):453–9.PubMed
82.
Adams PC, Kertesz AE. Human leukocyte antigen typing of siblings in hereditary hemochromatosis: a cost approach. Hepatology. 1992;15(2):263–8.CrossRefPubMed
83.
Beutler E, Gelbart T. Large-scale screening for HFE mutations: methodology and cost. Genet Test. 2000;4(2):131–42.CrossRefPubMed
84.
Ropert-Bouchet M, Fajardy I, Michel H. Hereditary hemochromatosis HFE: regulatory and economic aspects of diagnosis and medical management. Ann Biol Clin (Paris). 2012;70(4):405–11.
85.
86.
Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology. 1995;22(6):1720–7.PubMed
87.
Schoffski O, Schmidtke J, Stuhrmann M. Cost-effectiveness of population-based genetic hemochromatosis screening. Community Genet. 2000;3(1):2–11.CrossRef
88.
El-Serag HB, Inadomi JM, Kowdley KV. Screening for hereditary hemochromatosis in siblings and children of affected patients: a cost-effectiveness analysis. Ann Intern Med. 2000;132(4):261–9.CrossRefPubMed
89.
Delaveyne R, Préaubert N, Barré S. Clinical and economic assessment of screening for HFE1 haemochromatosis in 2004. L’Agence Nationale d’Accreditation d’Evaluation en Sante (ANAES) Paris; 2004.
90.
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0, J.P.T. Higgins, Green S, editors. The Cochrane Collaboration; 2011.
91.
Popay J, et al. Guidance on the conduct of narrative synthesis in systematic reviews. UK: ESRC Methods Programme; 2006.
92.
Balan V, et al. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology. 1994;107(2):453–9.PubMed
93.
Patch C, Roderick P, Rosenberg W. Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: assessment of anxiety, depression, and perception of health. Genet Med. 2005;7(8):550–6.CrossRefPubMed
94.
Beutler E, et al. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133(5):329–37.CrossRefPubMed
95.
Asberg A, et al. Benefit of population-based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol. 2002;37(10):1212–9.CrossRefPubMed
96.
Uhlig T, et al. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34(6):1241–7.PubMed
97.
Dan AA, et al. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl. 2008;14(3):321–6.CrossRefPubMed
98.
Fryback DG, et al. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Med Care. 2007;45(12):1162–70.PubMedCentralCrossRefPubMed
99.
Adams PC, Speechley M. The effect of arthritis on the quality of life in hereditary hemochromatosis. J Rheumatol. 1996;23(4):707–10.PubMed
100.
Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care. 2006;22(3):327–37.CrossRefPubMed
101.
102.
Sahinbegovic E, et al. Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum. 2010;62(12):3792–8.CrossRefPubMed
103.
Barton JC, et al. Characteristics of participants with self-reported hemochromatosis or iron overload at HEIRS Study initial screening. Am J Hematol. 2008;83(2):126–32.PubMedCentralCrossRefPubMed
104.
McLaren GD, et al. Clinical manifestations of hemochromatosis in HFE C282Y homozygotes identified by screening. Can J Gastroenterol. 2008;22(11):923–30.PubMedCentralPubMed
105.
McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Mak. 2008;28(4):582–92.CrossRef
106.
Lung TW, et al. A meta-analysis of health state valuations for people with diabetes: explaining the variation across methods and implications for economic evaluation. Qual Life Res. 2011;20(10):1669–78.CrossRefPubMed
107.
Holland R, et al. Patients’ self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death. J Card Fail. 2010;16(2):150–6.PubMedCentralCrossRefPubMed
Metadaten
Titel
A Systematic Review and Narrative Synthesis of Health Economic Studies Conducted for Hereditary Haemochromatosis
verfasst von
Barbara de Graaff
Amanda Neil
Kristy Sanderson
Lei Si
Kwang Chien Yee
Andrew J. Palmer
Publikationsdatum
01.10.2015
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 5/2015
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.1007/s40258-015-0189-y

Weitere Artikel der Ausgabe 5/2015

Applied Health Economics and Health Policy 5/2015 Zur Ausgabe

Systematic Review

A Systematic Review of Economic Evaluations of the Use of Robotic Assisted Laparoscopy in Surgery Compared with Open or Laparoscopic Surgery

Original Research Article

The Robustness and Effectiveness of the Triage System at Times of Overcrowding and the Extra Costs due to Inappropriate Use of Emergency Departments

Original Research Article

Valuing Child Health Utility 9D Health States with Young Adults: Insights from a Time Trade Off Study

Original Research Article

Implementing Guidelines: The Cost and Clinical Impact of Anticoagulants in the UK Atrial Fibrillation Population

Original Research Article

A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda

Commentary

Medicare’s Mission to Change How Health Care is Paid for and Delivered: A Cloud with a Silver Lining or Just a Dark Cloud?